首页> 外文期刊>International Journal of Hematology and Oncology >Type-I Hypersensitivity Reaction Secondary to Deferasirox Intake
【24h】

Type-I Hypersensitivity Reaction Secondary to Deferasirox Intake

机译:地拉罗司摄入继发的I型超敏反应

获取原文
           

摘要

Deferasirox is a new generation tridentate iron chelator. We report a ten-year old ?-thalassaemic boy, who had type-I hypersensitivity reaction due to deferasirox intake. At the seventh day of deferasirox treatment, he admitted to our clinic with the complaints of pruritic skin rash which began from the neck that spreaded throughout the body. After the termination of deferasirox treatment, the rash didn't recur. When deferasirox was restarted, similar skin rashes reappeared immediately. The skin prick, intradermal and patch tests and oral deferasirox provocation test were performed after 1 year, and the former reaction did not appear. Here in we showed when the defasirox was used first time even it caused some allergic reactions, however during the time period it can be used again due to the possibility of development of immune tolerance.
机译:Deferasirox是新一代三齿铁螯合剂。我们报告了一个十岁的β-地中海贫血男孩,由于服用了deferasirox而发生了I型超敏反应。在地拉罗司治疗的第七天,他因瘙痒性皮疹的主诉而进入我们的诊所,瘙痒性皮疹从颈部扩散到全身。地拉罗司治疗终止后,皮疹不再复发。重新启动地拉罗司后,立即出现类似的皮疹。一年后进行皮肤刺,皮内和斑贴试验以及口服地拉罗司激发试验,但未出现前者反应。在这里,我们显示了首次使用defasirox时甚至会引起一些过敏反应,但是在这段时间内,由于可能会产生免疫耐受,因此可以再次使用defasirox。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号